



O Gautschi

Kontakt

O Gautschi

Publikationen (8)

Panje C, Schwenkglens M, Gautschi O, Plasswilm L, Aebersold D, Dedes K, Lorez M, Pardo E, Barbier M, Lupatsch J, Swiss Group for Clinical Cancer Research (SAKK). A cost-effectiveness analysis of consolidation immunotherapy with durvalumab in stage III NSCLC responding to definitive radiochemotherapy in Switzerland. *Ann Oncol* 2020; 31:501-506.

Mazières J, Rothschild S, Bironzo P, Martinez A, Curioni-Fontecedro A, Rosell R, Lattuca-Truc M, Wiesweg M, Besse B, Solomon B, Barlesi F, Schouten R, Wakelee H, Camidge D, Zalcman G, Novello S, Ou S, Milia J, Zhu V, Sabari J, Drilon A, Lusque A, Mhanna L, Cortot A, Mezquita L, Thai A, Mascoux C, Couraud S, Veillon R, Van Den Heuvel M, Neal J, Peled N, Früh M, Ng T, Gounant V, Popat S, Diebold J, Gautschi O. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. *Ann Oncol* 2019

Schmid S, Jochum W, Demmer I, Foerbs D, Janthur W, Wannesson L, Rothschild S, Pless M, Gautschi O, Britschgi C, Aeppli S, Klingbiel D, Früh M. Patterns of progression on osimertinib in EGFR T790M positive NSCLC: A Swiss cohort study. *Lung Cancer* 2019; 130:149-155.

Griesinger F, Gautschi O, Früh M, Pirker R, Wiewrodt R, Brugger W, Schulz C, Sebastian M, Kimmich M, Deschler-Baier B, Lüers A, Radke S, Wolf J. [Strategies to Overcome Acquired Resistance to EGFR-TKI Therapy Based on T790M Specific Substances using Osimertinib as an Example]. *Pneumologie* 2018; 72:774-781.

Früh M, Ris H, Xyrafas A, Peters S, Mirimanoff R, Gautschi O, Pless M, Stupp R. Preoperative chemoradiotherapy with cisplatin and docetaxel for stage IIIB non-small-cell lung cancer: 10-year follow-up of the SAKK 16/01 trial. *Ann Oncol* 2016; 27:1971-3.

Mazières J, Milia J, Moro-Sibilot D, Cortot A, Cappuzzo F, Westeel V, Fournel P, Wislez M, Rosell R, Pless M, Früh M, Dansin E, Peters S, Beau-Faller M, Monnet I, Besse B, Filleron T, Barlesi F, Gautschi O. Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort. *Ann Oncol* 2015; 27:281-6.

Jörger M, Zappa F, Klingbiel D, Brauchli P, Rothschild S, Gautschi O, Pless M, Ochsenbein A, von Moos R, Betticher D, Stahel R, Droege C, Früh M, Baty F, Brutsche M. Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05). *Lung Cancer* 2014; 85:306-13.

Helbling D, Bougel S, Leibundgut E, Benhattar J, Yan P, Baertschi D, Borner M, Widmer L, Saletti P, Rauch D, Madlung A, Winterhalder R, Burkhard R, Gloor B, Bosman F, Sun H, Gautschi O, Bodoky G, Köberle D. Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07. *Ann Oncol* 2012; 24:718-25.

Projekte (0)

Keine Resultate gefunden.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch